Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Document date: 2020_4_17
ID: 1fgnfh62_66
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.16.044016 doi: bioRxiv preprint ONO-5334 was well tolerated up to daily doses of 300 mg and for up to 12 months without any clinically relevant safety concerns. ONO5334 reached phase II clinical trials for the treatment of osteoporosis in postmenopausal women, but development was discontinued due to an unfavorable competitive landscape 81.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.16.044016 doi: bioRxiv preprint ONO-5334 was well tolerated up to daily doses of 300 mg and for up to 12 months without any clinically relevant safety concerns. ONO5334 reached phase II clinical trials for the treatment of osteoporosis in postmenopausal women, but development was discontinued due to an unfavorable competitive landscape 81, 82 . VBY-825, which is in preclinical development, is another cathepsin inhibitor harboring potential antiviral activities against SARS-CoV-2 with an EC50 of ~300 nM, and it shows high potency against cathepsins B, L, S and V in vitro 83 . Overall, the identification of VBY-825 and ONO 5334 as effective antiviral molecules against SAR-COV-2 supports the repositioning of these, and potentially additional protease inhibitors, for the treatment of COVID-19 disease.
Search related documents:
Co phrase search for related documents- antiviral activity and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- antiviral activity and competitive landscape: 1
- antiviral activity and daily dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- antiviral activity and disease treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antiviral activity and high potency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- antiviral activity and preclinical development: 1, 2
- antiviral activity and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
- antiviral activity and safety concern: 1
- antiviral molecule and cathepsin inhibitor: 1
- antiviral molecule and clinical trial: 1, 2
- antiviral molecule and daily dose: 1, 2
- antiviral molecule and disease treatment: 1, 2, 3, 4, 5
- antiviral molecule and high potency: 1
- antiviral molecule and protease inhibitor: 1, 2
- cathepsin inhibitor and disease treatment: 1, 2
- cathepsin inhibitor and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- clinical trial and daily dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- clinical trial and disease treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical trial and high potency: 1, 2
Co phrase search for related documents, hyperlinks ordered by date